BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21337522)

  • 1. Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 β-hydroxysteroid dehydrogenase Type 1 (17 β-HSD1): the role of the bicyclic moiety.
    Oster A; Klein T; Henn C; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    ChemMedChem; 2011 Mar; 6(3):476-87. PubMed ID: 21337522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases.
    Oster A; Hinsberger S; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    J Med Chem; 2010 Nov; 53(22):8176-86. PubMed ID: 20977238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
    Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
    Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis.
    Wetzel M; Gargano EM; Hinsberger S; Marchais-Oberwinkler S; Hartmann RW
    Eur J Med Chem; 2012 Jan; 47(1):1-17. PubMed ID: 21945251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC
    Abdelsamie AS; van Koppen CJ; Bey E; Salah M; Börger C; Siebenbürger L; Laschke MW; Menger MD; Frotscher M
    Eur J Med Chem; 2017 Feb; 127():944-957. PubMed ID: 27852458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of 17β-HSD1: SAR of bicyclic substituted hydroxyphenylmethanones and discovery of new potent inhibitors with thioether linker.
    Abdelsamie AS; Bey E; Hanke N; Empting M; Hartmann RW; Frotscher M
    Eur J Med Chem; 2014 Jul; 82():394-406. PubMed ID: 24929290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
    Bey E; Marchais-Oberwinkler S; Werth R; Negri M; Al-Soud YA; Kruchten P; Oster A; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2008 Nov; 51(21):6725-39. PubMed ID: 18855374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
    Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
    Xu K; Al-Soud YA; Wetzel M; Hartmann RW; Marchais-Oberwinkler S
    Eur J Med Chem; 2011 Dec; 46(12):5978-90. PubMed ID: 22037253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
    Bey E; Marchais-Oberwinkler S; Negri M; Kruchten P; Oster A; Klein T; Spadaro A; Werth R; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2009 Nov; 52(21):6724-43. PubMed ID: 19831396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
    Starcević S; Brozic P; Turk S; Cesar J; Rizner TL; Gobec S
    J Med Chem; 2011 Jan; 54(1):248-61. PubMed ID: 21138273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
    Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
    J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
    Al-Soud YA; Bey E; Oster A; Marchais-Oberwinkler S; Werth R; Kruchten P; Frotscher M; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):212-5. PubMed ID: 18848601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis for species specific inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1): computational study and biological validation.
    Klein T; Henn C; Negri M; Frotscher M
    PLoS One; 2011; 6(8):e22990. PubMed ID: 21857977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
    Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1.
    Spadaro A; Frotscher M; Hartmann RW
    J Med Chem; 2012 Mar; 55(5):2469-73. PubMed ID: 22277094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards the evaluation in an animal disease model: Fluorinated 17β-HSD1 inhibitors showing strong activity towards both the human and the rat enzyme.
    Abdelsamie AS; Bey E; Gargano EM; van Koppen CJ; Empting M; Frotscher M
    Eur J Med Chem; 2015 Oct; 103():56-68. PubMed ID: 26322835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).
    Spadaro A; Negri M; Marchais-Oberwinkler S; Bey E; Frotscher M
    PLoS One; 2012; 7(1):e29252. PubMed ID: 22242164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.